Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 4 Prostatic Neoplasms 2 Multiple Myeloma 2 Melanoma 2 Kidney Neoplasms 2 Head and Neck Neoplasms 2 Breast Neoplasms 2 Waldenstrom Macroglobulinemia 1 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Tongue Neoplasms 1 Thyroid Neoplasms 1 Thymus Neoplasms 1 Testicular Neoplasms 1 Substance-Related Disorders 1 Stomach Neoplasms 1 Skin Neoplasms 1 Sarcoma, Synovial 1 Sarcoma, Kaposi 1 Sarcoma 1 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pheochromocytoma 1 Pharyngeal Neoplasms 1 Penile Neoplasms 1

Interventions

Fentanyl 19 Analgesia 15 Acupuncture Therapy 13 Oxycodone 12 Zoledronic Acid 11 Surveys and Questionnaires 10 nabiximols 9 Therapeutics 9 Morphine 9 Acetaminophen 9 Psychiatric Rehabilitation 8 Ketamine 8 Hydromorphone 7 Lidocaine 6 Ibandronic Acid 6 Radiotherapy 5 Early Intervention, Educational 5 Bupivacaine 5 Analgesics, Opioid 5 Yoga 4 Transcutaneous Electric Nerve Stimulation 4 Therapeutic Touch 4 Ropivacaine 4 Music Therapy 4 Methadone 4 Massage 4 Aromatherapy 4 alvimopan 3 Tapentadol 3 Saline Solution 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Pain × Patient Reported Outcome Measures × Clear all

NCT05684939 2023-06-13

CAPS

University Hospital, Clermont-Ferrand

Neoplasms, Pain, Substance-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡